96886-46-3

Upstream product

• 142-84-7 di-n-propylamine 
• 4693-91-8 4-methoxyphenyl-acetic chloride 
• 51-67-2 tyrosamine 
• 123-38-6 propionaldehyde 
• 96886-44-1 N,N-di-n-propyl-4-methoxyphenylacetamide 
• 96886-45-2 4-methoxy-N,N-di-n-propylphenethylamine 

Downstream Products

• 96886-47-4 4-hydroxy-3-nitro-N,N-di-n-propylphenethylamine 
• 104102-91-2 3-amino-4-(benzyloxy)-N,N-di-n-propylphenethylamine 
• 101566-36-3 3-acetamido-4-hydroxy-N,N-di-n-propylphenethylamine 
• 101566-34-1 3-formamido-4-hydroxy-N,N-n-dipropylphenethylamine 
• 110925-48-9 N-[2-Benzyloxy-5-(2-dipropylamino-ethyl)-phenyl]-acetamide 
• 96886-51-0 4-(benzyloxy)-3-nitro-N,N-di-n-propylphenethylamine 
• 104103-26-6 N-[2-benzyloxy-5-(2-dipropylaminoethyl)phenyl]formamide 

Relevant academic research and scientific papers

AMINE COMPOUNDS AND USE THEREOF

It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1):In a typical case, A1 and A2 represent each an optionally substituted monocyclic or polycyclic aromatic heterocycle; W represents cyclic C3-10 alkylene, an optionally substituted monocyclic or polycyclic aromatic heterocycle, a monocyclic or polycyclic aromatic ring or a partly saturated polycyclic aromatic ring; X represents O, CH2, C(=O) or NR11; and D is a group represented by the following general formula (4) or (6).-Q-Y-BIn the formula (6), Q represents a single bond, S, O or NR12; and Y is a group represented by the following general formula (7). z represents an optionally substituted monocyclic or polycyclic aromatic ring. In the formula (6), B represents NR25R26. In the above formulae, R1 to R26 each represents hydrogen, alkyl, alkenyl or alkynyl.

Syntheses and in Vitro Evaluation of 4-(2-Aminoethyl)-2(3H)-indolones and Related Compounds as Peripheral Prejunctional Dopamine Receptor Agonists

A series of (β-aminoethyl)indolones and related compounds was synthesized and evaluated in vitro as peripheral prejunctional dopaminergic agonists in the field-stimulated isolated perfused rabbit ear artery. 4--7-hydroxy-2(3H)-indolone (26) was the most potent compound (ED50 = 2 +/- 0.3 nM) tested, while the related secondary amine 24 and the des-OH derivatives 28 and 34 were only slightly less potent. 4-Methoxy-benzeneethanamine and 2-methyl-3-nitrophenylacetic acid were employed as starting materials for the synthesis of the 4-(β-aminoethyl)indolones.The ring-opened 3-acylamino analogues 46 and 47 were prepared via nitration of the phenethylamine 43 derived from 4-methoxyphenylacetic acid.The inactive isomeric indolones 38, 39, and 41 were derived from 4-nitrobenzeneethanamine and from indolone-6-acetic acid (13).

Dopaminergic agonist N,N-di-n-propyl-4-hydroxy-3-methanesulfonamidophenethylamine

N,N-Di-n-propyl-4-hydroxy-3-methanesulfonamidophenethylamine is a potent, selective presynaptic dopaminergic agonist. The compound is prepared by N-sulfonylation of an optionally O-protected derivative of 3-amino-4-hydroxy-N,N-di-n-propylphenethylamine, f